UNICYCIVE THERAPEUTICS UNCY 深 沪
已收盘 08-01 16:00:00 美东时间
4.20
-0.140
-3.23%
华盛通- 最 高4.32
- 今 开4.26
- 成交量 37.64万股
- 最 低 4.10
- 昨 收 4.34
- 总市值 5309.18万
- 52周最高 11.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.02
- 委 比 26.01%
- 总股本 1264.09万
- 历史最高 87.30
- 量 比 1.04
- 振 幅 5.07%
- 历史最低 2.02
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
A Phase 2 clinical trial of Oxylanthanum Carbonate (OLC) showed that the investigational phosphate binder effectively controlled serum phosphate levels in over 90% of chronic kidney disease (CKD) patients on dialysis with hyperphosphatemia. OLC was well-tolerated, with only 4% of patients discontinuing due to adverse events, and required a low pill burden (three or fewer tablets/day for two-thirds of patients). The trial results support OLC's pot...
07-24 12:00
Unicycive Regains Nasdaq Compliance After Stock Split
Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. On July 8, 2025,...
07-08 21:28
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Unicycive Therapeutics reache Neuer Marktanhängigkeit an der NASDAQ nach erfolgreicher Umsetzung eines 1:10-rückwärtigen Aktiensplits.
07-08 12:30
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Unicycive Therapeutics首席执行官Shalabh Gupta博士将于7月14日美国东部时间上午11点，在H.C. Wainwright 4th Annual Kidney Virtual Conference上参与炉边谈话。会议链接可在公司网站投资者部分访问。Unicycive致力于开发肾脏疾病治疗药物，重点为oxylanthanum carbonate（治疗慢性肾病患者高磷血症）和UNI-494（针对急性肾损伤，已获FDA孤儿药指定用于预防肾移植患者的延迟移植物功能）。
07-07 11:00
Unicycive drops 25% following Complete Response Letter
Unicycive Therapeutics (NASDAQ:UNCY) is down ~25% after disclosing it has received a Complete Response Letter from the U.S. FDA for its application for oxylanthanum carbonate. The candidate aims to tr...
06-30 23:04
Unicycive Therapeutics shares are trading lower after the company announced the FDA has issued a Complete Response Letter for its new drug application and cited deficiencies.
Unicycive Therapeutics shares are trading lower after the company announced the...
06-30 20:28
Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Unicycive Therapeutics' New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The CRL cited deficiencies at a third-party manufacturing vendor unrelated to OLC, with no other concerns raised regarding pre-clinical, clinical, or safety data. The Company identified a secon...
06-30 11:05
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock moved upwards by 19.6% to $0...
06-26 05:06
单日暴涨130%+，肾病领域再成行业焦点
转自：新康界 4月30日，诺华公司宣布以17亿美元收购美股上市医药公司Regulus(NASDAQ:RGLS)，受此消息影响，Regulus的股价...
06-23 19:50
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Acurx Pharmaceuticals (NASDAQ:ACXP) stock moved upwards by 235.5% to $...
06-17 20:08
